Natural and synthetic compounds suppress inflammasome activation in NLRP3-driven pathologies

This systematic review evaluated the potential of natural compounds, including oridonin and pristimerin, as well as synthetic inhibitors like MCC950 and entrectinib, in targeting NLRP3-driven pathologies. The scope included conditions such as gouty arthritis, ischemia-reperfusion injury, neurodegenerative disorders, and metabolic syndromes. The review did not report a specific population, sample size, or clinical setting, focusing instead on mechanistic evidence derived from upstream regulatory networks.

The primary outcome assessed was the suppression of inflammasome activation. Evidence indicates that both natural compounds and synthetic inhibitors disrupt the NEK7-NLRP3 interaction, a critical step in inflammasome assembly. This disruption leads to the suppression of inflammasome activation. However, the review did not provide absolute numbers, effect sizes, or p-values for these mechanistic observations.

Safety and tolerability data were not reported in the review. Adverse events, serious adverse events, discontinuations, and general tolerability profiles for these agents were not described. The review also did not specify a comparator group for the interventions. Consequently, the clinical safety profile of these specific compounds in human trials remains undefined based on this evidence.

Key limitations include the absence of reported patient populations, sample sizes, and follow-up durations. The study design was a review of molecular mechanisms rather than a clinical trial, which limits direct translation to patient outcomes. Funding sources and conflicts of interest were not reported. The practice relevance is identified as novel therapeutic strategies, but the certainty is constrained by the mechanistic nature of the data and the lack of reported adverse events.